Long QT Syndrome (Schwartz Score)
Estimates probability of congenital Long QT Syndrome using Schwartz-Moss criteria. Guides genetic testing, beta-blocker therapy, and ICD consideration.
Score interpretation
→ LQTS unlikely; check QTc-prolonging medications; genetic testing if clinical suspicion remains; family history review
→ Electrophysiology and genetics referral; genetic testing (KCNQ1, KCNH2, SCN5A); exercise ECG; avoid QT-prolonging drugs; check crediblemeds.org
→ Beta-blocker (nadolol or propranolol) — first-line; avoid QT-prolonging drugs; electrolyte correction; genetic testing mandatory; family screening; ICD for high-risk patients (prior VF, breakthrough symptoms on beta-blockers)
Interpretation bands for the LQTS Schwartz Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Pancuronium bromide · Long-acting non-depolarising neuromuscular blocker
- Metoprolol (IV/Oral — Cardiology) · Beta-Blocker
- Carvedilol · Beta-Blocker / HFrEF
- Acebutolol · Beta-blocker
- Sotalol hydrochloride · Class III antiarrhythmic + non-selective β-blocker
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.